Malignant nephrosclerosis is histologically similar to atypical hemolytic uremic syndrome (aHUS), a disease that has been shown to be curable by complement inhibition therapy using the C5 cleavage inhibitor eculizumab, and is presented with features such as complement deposition, inflammation, and thrombotic microangiopathy [14, 15]. Here, C5 is linked to atypical hemolytic-uremic syndrome.